Back to top
more

Tandem Diabetes Care (TNDM)

(Delayed Data from NSDQ)

$15.40 USD

15.40
1,385,256

-0.18 (-1.16%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $15.39 -0.01 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Tandem Diabetes (TNDM) and Abbott Debut New Integrated Offering

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:slim X2 is the first AID system to be integrated with Abbott's Freestyle Libre 2 Plus sensor.

Zacks Equity Research

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors remain optimistic about Tandem Diabetes (TNDM), backed by the impressive spree of product introductions.

Zacks Equity Research

Tandem Diabetes (TNDM) Avails Tandem Source in the United States

by Zacks Equity Research

Tandem Diabetes (TNDM) announces the full U.S. launch of Tandem Source, a new diabetes management platform for customers and healthcare providers.

Zacks Equity Research

Tandem Diabetes (TNDM) Launches Dexcom G7 Integrated t:slim X2

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:slim X2 is the first AID system in the world to feature Dexcom's most advanced CGM technology.

Zacks Equity Research

Why Is Tandem Diabetes Care, Inc. (TNDM) Up 33.2% Since Last Earnings Report?

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors remain optimistic about Tandem Diabetes (TNDM), backed by upcoming innovative launches, including Mobi and the new integrated CGM offering.

Zacks Equity Research

Tandem Diabetes (TNDM) Posts Wider Q3 Loss, Trims '23 Sales View

by Zacks Equity Research

Tandem Diabetes (TNDM) reports a higher-than-anticipated loss in the third quarter of 2023.

Zacks Equity Research

Compared to Estimates, Tandem Diabetes Care, Inc. (TNDM) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Tandem Diabetes Care, Inc. (TNDM) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Urmimala Biswas headshot

MedTech Stocks' Q3 Earnings Due on Nov 1: IDXX, EXAS & More

by Urmimala Biswas

MedTech companies' third-quarter results are likely to reflect a year-over-year decline. Let's see how IDXX, EXAS, TNDM and NVST fare this time.

Zacks Equity Research

Analysts Estimate Tandem Diabetes Care, Inc. (TNDM) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Integra LifeSciences (IART) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of -2.56% and 1.35%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) Soars 6.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors remain optimistic about Tandem Diabetes (TNDM), backed by strategic developments and innovative new launches.

Zacks Equity Research

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Zacks Equity Research

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors continue to be optimistic about Tandem Diabetes (TNDM) due to the t:slim X2 insulin pump and new product innovations.

Zacks Equity Research

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Zacks Equity Research

Tandem Diabetes (TNDM) Reports Narrower Q2 Loss, Trims '23 View

by Zacks Equity Research

Tandem Diabetes' (TNDM) second-quarter 2023 performance reflects new technology innovations and operational improvements throughout its business.

Zacks Equity Research

Compared to Estimates, Tandem Diabetes Care, Inc. (TNDM) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Tandem Diabetes Care, Inc. (TNDM) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of 44.44% and 2.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tandem Diabetes (TNDM) Gets FDA Nod for Tandem Mobi System

by Zacks Equity Research

Tandem Diabetes (TNDM) receives FDA clearance for the world's smallest AID system, Tandem Mobi.

Zacks Equity Research

Strength Seen in Tandem Diabetes Care, Inc. (TNDM): Can Its 8.9% Jump Turn into More Strength?

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors continue to be optimistic about Tandem Diabetes (TNDM) based on the strong performance of the t:slim X2 insulin pump.

Zacks Equity Research

Tandem Diabetes (TNDM) Q1 Earnings Miss, Gross Margin Dips

by Zacks Equity Research

According to Tandem Diabetes (TNDM), Q1 revenues are in line with the high end of its expectations.

Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -12.50% and 1.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will KORU Medical Systems Inc. (KRMD) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

KORU Medical Systems Inc. (KRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.